[
1. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, Di-Nardo C, et al. Treating Leukemia in the Time of COVID-19. Acta Haematol 2021;144:132-45. DOI: 10.1159/00050819910.1159/000508199
]Search in Google Scholar
[
2. Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (Accessed on April 5, 2021).
]Search in Google Scholar
[
3. Uzzo R, Kutikov A, Geynisman D, Michael B Atkins, Larissa Nekhlyudov, Richard A Larson et al. COVID-19: Risks for infection, clinical presentation, testing, and approach to infected patients with cancer, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on 02 Apr, 2021).
]Search in Google Scholar
[
4. Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 Jul;10(7):935-41. DOI: 10.1158/2159-8290.CD-20-051610.1158/2159-8290.CD-20-0516
]Search in Google Scholar
[
5. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020 May;55:102763. DOI: 10.1016/j.ebiom.2020.10276310.1016/j.ebiom.2020.102763
]Search in Google Scholar
[
6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Apr 6;46(5):846-8. DOI: 10.1007/s00134-020-05991-x10.1007/s00134-020-05991-x
]Search in Google Scholar
[
7. Centers for Disease Control and Prevention. Science brief: Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlying-evidence-table.html (Accessed on April 5, 2021).
]Search in Google Scholar
[
8. El-Sharkawi D, Iyengar S. Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date. Br J Haematol. 2020;190: 336-45. DOI: 10.1111/bjh.1695610.1111/bjh.16956
]Search in Google Scholar
[
9. Borah P, Mirgh S, Sharma SK, Bansal S, Dixit A, Dolai TK, et al, AIIMS Hematology Alumni Group. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis. 2021 Mar;87:102525. DOI: 10.1016/j.bcmd.2020.10252510.1016/j.bcmd.2020.102525
]Search in Google Scholar
[
10. Popov VM, Iliescu L, Balea MI, Horatiu Ioani, Mihaela Andreescu, Daniela Georgescu, et al. Predictive value of hematologic and coagulation parameters in assessment of severity and evolution of COVID-19 patients. Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X). 2020 October;8(10);605-15.
]Search in Google Scholar
[
11. Pi-ana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G. Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020 Aug 25;9:21. DOI: 10.1186/s40164-020-00177-z10.1186/s40164-020-00177-z
]Search in Google Scholar
[
12. Fattizzo B, Giannotta JA, Sciumè M, Cattaneo D, Bucelli C, Fracchiolla NS, et al. Reply to „COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality. Leukemia. 2020 Jul;34(7):1957-60. DOI: 10.1038/s41375-020-0877-y10.1038/s41375-020-0877-y
]Search in Google Scholar
[
13. Liu J, Liu Y, Xiang P, Xiong H, Li C, Zhang M, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206. DOI: 10.1186/ s12967-020-02374-010.1186/s12967-020-02374-0
]Search in Google Scholar
[
14. Rubinstein SM, Warner JL. COVID-19 and haemato-logical malignancy: navigating a narrow strait. Lancet Haematol. 2020 Oct;7(10):e701-3. DOI: 10.1016/ S2352-3026(20)30252-010.1016/S2352-3026(20)30252-0
]Search in Google Scholar
[
15. Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, Lin S. COVID-19 in posttransplant patients-report of 2 cases. Am J Transplant. 2020 Jul;20(7):1879-81. DOI: 10.1111/ajt.1589610.1111/ajt.15896
]Search in Google Scholar
[
16. Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, La-very JA, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020 Dec 1;130(12):6656-67. DOI: 10.1172/ JCI14177710.1172/JCI141777
]Search in Google Scholar
[
17. Ciccullo A, Borghetti A, Zileri Dal Verme L, Tosoni A, Lombardi F, Garcovich M, et al; GEMELLI AGAINST COVID Group. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents. 2020 Aug;56(2):106017. DOI: 10.1016/j.ijantimicag.2020.10601710.1016/j.ijantimicag.2020.106017
]Search in Google Scholar
[
18. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 Oct;7(10):e737-45.10.1016/S2352-3026(20)30251-9
]Search in Google Scholar
[
19. Chan AS, Rout A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. J Clin Med Res. 2020 Jul;12(7):448-53. DOI: 10.14740/ jocmr424010.14740/jocmr4240733186132655740
]Search in Google Scholar
